# Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients

> **NCT01198522** · PHASE1 · TERMINATED · sponsor: **Philogen S.p.A.** · enrollment: 28 (actual)

## Conditions studied

- Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection

## Interventions

- **DRUG:** L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine

## Key facts

- **NCT ID:** NCT01198522
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** lack of recruitment
- **Last updated:** 2022-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01198522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01198522, "Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01198522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*